-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$16.3383.48% Upside
Foghorn Therapeutics Inc. Frequently Asked Questions
-
What analysts cover Foghorn Therapeutics Inc.?
Foghorn Therapeutics Inc. has been rated by research analysts at Morgan Stanley, Evercore ISI, BMO Capital in the past 90 days.